Research To Practice | Oncology Videos

Featuring an interview with Dr Matthew Matasar, including the following topics: Rationale for the evaluation of anti-CD20 x CD3 bispecific antibodies in the treatment of non-Hodgkin lymphoma (NHL) (0:00) Incidence, severity and time course of cytokine release syndrome, neurotoxicity/ICANS and other adverse events associated with bispecific antibodies; recommended mitigation and management protocols (4:39) Activity of and similarities and differences among the various bispecific antibodies for NHL (12:20) Eligibility, efficacy and durability of response with mosunetuzumab, glofitamab, epcoritamab and odronextamab; ongoing and planned evaluations of bispecific antibodies alone and in combination with other systemic therapies (19:18) Optimal integration of bispecific antibody platforms into treatment algorithms for patients with NHL (32:12) Emerging results with bispecific antibodies for mantle cell lymphoma and chronic lymphocytic leukemia (41:51) CME information and select publications

Featuring perspectives from Dr Kathleen N Moore, including the following topics: Introduction: SOLO-1 Trial (0:00) Case: A woman in her mid 50s with a germline BRCA1 mutation who received IV/IP chemotherapy followed by olaparib maintenance experiences disease recurrence — Neil Morganstein, MD (15:58) Case: A woman in her late 50s with a germline BRCA2 mutation undergoes surgery and chemotherapy for Stage II high-grade serous ovarian cancer (HGSOC) — Kellie E Schneider, MD (24:38) Case: A woman in her late 70s with a somatic BRCA2 mutation and Stage IVB HGSOC who experienced disease progression on the placebo arm of the PRIMA trial and recurrence in 2019 receives liposomal doxorubicin/carboplatin and maintenance niraparib — Karim ElSahwi, MD (30:37) Case: A woman in her early 50s presents with recurrent BRCA wild-type (WT), homologous recombination deficiency (HRD)-negative clear cell ovarian cancer after interval debulking surgery — Dana M Chase, MD (35:16) Case: A woman in her early 60s with BRCA WT, HRD-negative, folate receptor alpha-positive ovarian cancer experiences primary disease progression on neoadjuvant carboplatin/paclitaxel and receives mirvetuximab soravtansine — Priya Rudolph, MD, PhD (46:49) Investigator Survey (58:37) CME information and select publications

Featuring a slide presentation and related discussion from Dr Philippe Moreau, including the following topics: General overview of anti-CD38 antibodies in therapy for multiple myeloma (MM) (0:00) Anti-CD38 antibodies as part of first-line therapy for transplant-ineligible patients with MM (2:35) Quadruplet versus triplet induction regimens with anti-CD38 antibodies for newly diagnosed, transplant-eligible patients with MM (7:44) Clinical trial data with anti-CD38 antibodies for patients with MM at first relapse (13:02) Treatment options for patients with MM at second relapse and beyond (18:09) Subcutaneous formulations of daratumumab and isatuximab; CD38 as a target for other therapeutic strategies (21:00) CME information and select publications

Featuring an interview with Prof Philippe Moreau, including the following topics: Perspectives on efficacy outcomes with and toxicity profiles of daratumumab and isatuximab (0:00) Selection of an anti-CD38 antibody for initial treatment of multiple myeloma (MM) (7:28) Approach to maintenance therapy for transplant-eligible patients with MM (15:47) Management of MM in older patients; treatment approaches for t(11;14) MM (22:47) Management of relapsed/refractory MM (29:49) Management of anti-CD38 antibody-associated side effects (35:45) Other relevant clinical scenarios in MM — Plasma cell leukemia, smoldering myeloma (41:19) Perspectives on the future landscape of up-front treatment for MM (45:02) CME information and select publications

Featuring perspectives from Dr Kristen K Ciombor and Dr J Randolph Hecht, including the following topics: Introduction (0:00) Case: A woman in her early 80s with KRAS-mutated, HER2-positive metastatic colorectal adenocarcinoma — Zanetta S Lamar, MD (14:29) Case: A man in his late 70s with metastatic KRAS G12C-mutated rectal adenocarcinoma treated with third-line sotorasib/panitumumab — Georges Azzi, MD (26:03) Cases: A man in his late 50s with KRAS-mutated metastatic colon cancer and very slow disease progression on second-line FOLFIRI/bevacizumab, and a man in his mid 40s with KRAS wild-type metastatic colon cancer and disease progression on third-line treatment — Priya Rudolph, MD, PhD, and Ina J Patel, DO (30:41) Case: A man in his early 80s with right-sided microsatellite-stable (MSS), KRAS G12D-mutated metastatic colorectal cancer (mCRC), tumor mutational burden 10 mut/Mb, currently receiving third-line TAS-102 — Warren S Brenner, MD (37:11) Case: A man in his late 70s with microsatellite instability-high, BRAF V600E-mutated recurrent cecal adenocarcinoma — Nikesh Jasani, MD (50:09) Cases: A woman in her late 50s with MSS BRAF V600E-mutated mCRC with brain and bone metastases who experiences a good response to dose-reduced FOLFOX after disease progression on first-line encorafenib/cetuximab, and a woman in her mid 60s with RAS wild-type, BRAF V600E-mutated, MSS mCRC, now receiving encorafenib/cetuximab after disease progression on FOLFOX/bevacizumab — Farshid Dayyani, MD, PhD, and Dr Azzi (59:05) CME information and select publications

Practical Perspectives: Investigators Discuss Current Management and Actual Cases of Relapsed/Refractory Metastatic Colorectal Cancer | Faculty Presentation 2: Targeted Treatment for R/R mCRC — J Randolph Hecht, MD CME information and select publications

Practical Perspectives: Investigators Discuss Current Management and Actual Cases of Relapsed/Refractory Metastatic Colorectal Cancer | Faculty Presentation 1: Nontargeted Treatment Approaches for Relapsed/Refractory (R/R) Metastatic Colorectal Cancer (mCRC) — Kristen K Ciombor, MD, MSCI CME information and select publications

Featuring an interview with Prof Naveen Pemmaraju, including the following topics: Case: A woman in her mid 20s with classic blastic plasmacytoid dendritic cell neoplasm (BPDCN) who responded to combination hyper-CVAD/venetoclax (0:00) Defining and diagnosing BPDCN (5:17) Presentation, prevention and management of capillary leak syndrome (7:56) Targeting CD123 in BPDCN (12:53) Case: A man in his early 70s with TET-mutated BPDCN who had a complete response to tagraxofusp (14:21) Selection of CD123-targeted therapy for patients with BPDCN (20:05) Case: A man in his mid 60s who had a complete response to pivekimab sunirine (27:04) Future directions in the treatment of BPDCN (28:55) CME information and select publications

Featuring a slide presentation and related discussion from Prof Naveen Pemmaraju, including the following topics: Overview of blastic plasmacytoid dendritic cell neoplasms (0:00) Tagraxofusp: Development of the first FDA-approved targeted therapy for BPDCN (9:07) Integration of pivekimab sunirine into the management of BPDCN (20:31) Emerging novel therapies for patients with BPDCN and current role of chemotherapy-based regimens (26:02) Future directions in the management of BPDCN (33:26) CME information and select publications

Featuring perspectives from Dr Prithviraj Bose and Dr Andrew T Kuykendall, moderated by Dr Mascarenhas, including the following topics: Introduction (0:00) Clinical Decision-Making for Patients with Myelofibrosis (MF) — Dr Bose (2:27) Management of MF in Special Patient Populations — Dr Mascarenhas (19:26) Future Directions in the Management of MF — Dr Kuykendall (48:09) CME information and select publications